Preapproval Inspection Mandate Dropped For Top Rxs; More Flexibility For Field
FDA will no longer mandate automatic preapproval inspections for the top 200 prescribed drugs and narrow therapeutic index drugs
You may also be interested in...
FDA expects to release a draft on improving the agency's good manufacturing practices management systems by Dec. 1
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials